Open | - |
Close | - |
Volume / Avg. | 0 / 783.895K |
Day Range | - - - |
52 Wk Range | 14.305 - 39.790 |
Market Cap | $1.656B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 38 |
Short Interest | 6.79% |
Days to Cover | 5.37 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Inhibrx (NASDAQ: INBX) through any online brokerage.
Other companies in Inhibrx’s space includes: Twist Bioscience (NASDAQ:TWST), Avidity Biosciences (NASDAQ:RNA), Gyre Therapeutics (NASDAQ:GYRE), 4D Molecular Therapeutics (NASDAQ:FDMT) and Syndax Pharmaceuticals (NASDAQ:SNDX).
The latest price target for Inhibrx (NASDAQ: INBX) was reported by JMP Securities on Tuesday, January 23, 2024. The analyst firm set a price target for 0.00 expecting INBX to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Inhibrx (NASDAQ: INBX) is $34.94 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Inhibrx.
Inhibrx’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Inhibrx.
Inhibrx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.